Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 3Completed 3Unknown 2Terminated 2Withdrawn 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 218Breast 88Head & Neck 13Other solid neoplasm 8Tumor-Agnostic 5Other neoplasm 2NET 2Lymphoid 2Endocrine 2Thoracic 1Sarcoma 1Gynecologic 1Dermatologic 1CNS 1

Conditions

Neuroendocrine Tumors 2Carcinoma, Neuroendocrine 1

Interventions

lutetium Lu 177 dotatate 4lanreotide 3Temozolomide 3177Lu-octreotide, DOTA(0)-Tyr(3)- 3(177)Lu-DOTA-EB-TATE 3anlotinib 2Positron Emission Tomography Computed Tomography 2N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 2Metformin 2Fluorodeoxyglucose F18 2Everolimus 2Etoposide 2Cisplatin 2Capecitabine 2Biopsy 2surufatinib 1sintilimab 1regorafenib 1recombinant interferon alpha 2b-like protein 1pembrolizumab 1gallium Ga 68 dotatate 1copper dotatate CU-64 1cabozantinib 1amino-acid, glucose, and electrolyte solution 1Yttrium-90 1Tomography, Emission-Computed, Single-Photon 1Thalidomide 1Tegafur 1Surgical Procedures, Operative 1Somatostatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × Capecitabine × NET × Clear all
NCT03279601 2017-09-12

Study to Compare Capecitabine Combined With Dacarbazine(CAPDTIC) Versus Capecitabine Combined Temozolomide(CAPTEM) in Advanced and Metastatic Gastrointestinal Pancreatic and Esophageal Neuroendocrine Tumor

Peking University

Phase 2 Unknown
148 enrolled
EndocrineNET

Neuroendocrine Tumors

NCT01203306 2010-09-16

XELBEVOCT

University of Turin, Italy

Phase 2 Unknown
42 enrolled
EndocrineNET

Carcinoma, Neuroendocrine, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡